相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Michael L. Mohler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
Yang Da et al.
MEDICINAL CHEMISTRY RESEARCH (2020)
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro tumor growth in vivo
Lijie Zhao et al.
NEOPLASIA (2020)
Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
Akshay D. Takwale et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target
Claudia Ferroni et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
Dong-Jin Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
Norihito Shibata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami et al.
COMMUNICATIONS BIOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents
Katherine J. Kayser-Bricker et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
分享论文
